Evangelia Stavrakoudi

Ms. Evangelia Stavrakoudi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2024 in Processes
Verified
Journal Article
Open access
PDF file
Theodora AdamantidiTheodora Adamantidi
Theodora Adamantidi
EPEllie Panoutsopoulou
Ellie Panoutsopoulou
ESEvangelia Stavrakoudi
Evangelia Stavrakoudi
PTPanagiota Tzevelekou
Panagiota Tzevelekou
Nikolaos C. KokkinosNikolaos C. Kokkinos
Nikolaos C. Kokkinos
The impact of COVID-19’s unexpected outbreak forced the scientific community to seek alternative treatment methods in order to overcome the hindrance of traditional medicine in terms of alleviating the symptoms of this virus. Erythromycin, which was introduced in 1952, is an antibiotic that is reported to pose as an effective substitute medication for various ailments such as skin, respiratory, bone, and female reproductive conditions, and cancer, as well as the newly added COVID-19. The importance of both the erythromycin molecule and the catalyst of its production, namely P450eryF of the cytochrome P450 family, in many health-concerned and environmentally related applications, has led several countries, the World Health Organization (WHO) and the health industry to recruit and cooperate with numerous universities and institutions, in an attempt to tackle the demand for efficient antibiotics. The aim of this study is to discuss and further analyze the overall structure and catalytic mechanism of erythromycin’s synthesis and industrial production, in order to gain a better comprehension of this molecule’s significance and value in the pharmaceutical field. This was carried out through the citation of the current production rates per country and the latest statistics and published patents. As implied in this manuscript, the demand for an increase and improvement in the production of erythromycin and its antibiotic derivatives should be globally promoted to deliver more effective results against infectious diseases, such as COVID-19.

7 December 2024 in Immuno
Verified
Journal Article
Open access
PDF file
GMGaryfallos Markou
Garyfallos Markou
EPEllie Panoutsopoulou
Ellie Panoutsopoulou
ESEvangelia Stavrakoudi
Evangelia Stavrakoudi
CMCharalampos Mylonas
Charalampos Mylonas
SISofia Ioannou
Sofia Ioannou
Alexandros TsouprasAlexandros Tsoupras
Alexandros Tsoupras
Human immunodeficiency virus (HIV) has troubled humankind for many years. The rate of new HIV cases is decreasing steadily, mostly because of safer sexual practices and scientific advances in medicine. However, the number of HIV-related trials has significantly increased, as the search for a definite cure for HIV is still fruitless. Our current treatment options involve antiretroviral therapy (ART) with various drug combinations that lower the patients’ viral load in order for the immune system to reconstitute itself. This way, adherent patients achieve a life expectancy similar to the general population. Besides the established treatment protocols, the focus has currently shifted towards secondary pharmaceutical regimen programs that enhance a patient’s immune system and response to opportunistic infections. Vitamins C and D are easily obtainable even in the developing world and are known to improve an individual’s daily life, with vitamin D enhancing the human immune response and vitamin C having an assisting role in both the immune response and as an important antioxidant. Recently, many studies assessing the effect of these vitamins on the progression of HIV have been performed. We aimed to collect and review these studies in order to determine the necessity of the supplementation of these vitamins in HIV-infected patients, which might complement the existing ART. To this day, the scientific community is conflicted, and more studies must be conducted before a definite conclusion about these vitamins’ effects on HIV patients can be reached.